PreciseDx is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology.
PreciseDx has raised $3.7M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in October 2026.
PreciseDx's investors include LabCorp, Agilent Technologies, Quest Diagnostics, IBM Ventures, Merck Global Health Innovation Fund.
PreciseDx is headquartered in New York, United States.
PreciseDx is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology.
PreciseDx is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"PreciseDx — Funding & Investors." VCBacked, October 7, 2026, https://www.vcbacked.co/company/precisedx. Accessed November 22, 2026.
VCBacked. (2026). PreciseDx — Funding & Investors. Retrieved November 22, 2026, from https://www.vcbacked.co/company/precisedx
{{cite web |title=PreciseDx — Funding & Investors |url=https://www.vcbacked.co/company/precisedx |website=VCBacked |access-date=November 22, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at PreciseDx? Request a listing update